Novocure Ltd at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44 Annual Healthcare Conference today with Novocure. First, you're going to hear a presentation from the company, and then we're going to have a Q&A session.
(Event Instructions). But with that out of the way, let me turn it over to the company's CEO, Frank Leonard.
Thank you, Jess. It's my privilege to be here today to present Novocure's preliminary 2025 results as well as look ahead to a catalyst-rich year in 2026. For those of you who don't know me, I have taken over as CEO just a few months ago, However, I've been with the company now for 15-plus years. And prior to that as a venture capital investor and part of the team that helped to bring the first institutional investments into Novocure.
And I, through that time, I've covered multiple areas for the company, including our product development, corporate strategy, reimbursement groups
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
